Science ❯ Biotechnology

Gene Therapy

Clinical Trials Viral Vectors Drug Development Research Funding Adeno-Associated Virus Cell Therapy Clinical Research Base Editing COVID-19 Vaccines In Vivo Products Gene Regulation Clinical Applications Cancer Treatments Personalized Medicine Regulation mRNA Applications RNA Medicines mRNA Technology FDA Approval Duchenne Muscular Dystrophy RNA Mechanisms RNA Editing ELEVIDYS Therapeutic Applications Neurodevelopmental Disorders RNA Therapy Genetic Disorders Messenger RNA uniQure RNA Engineering RNA Therapeutics Gene-Silencing Technology Immunosuppression Cellular Response Stem Cell Research Company Performance Vaccines

Lilly Licenses MeiraGTx Eye Gene Therapy in Deal Worth Up to $475 Million

The agreement deepens Lilly’s push into ophthalmic gene medicines following its October move to buy Adverum Biotechnologies.

Lilly to Buy Adverum in Gene‑Therapy Deal Worth Up to $12.47 a Share

FDA Names First 9 Drugs for ‘National Priority’ Fast-Track Reviews, Targeting 1–2-Month Decisions

Former FDA Biologics Chief Peter Marks Joins Eli Lilly to Lead Infectious Disease and Molecule Discovery

Gene Therapy Slows Huntington’s Progression by 75% in Early Trial, uniQure Says

Capsida Halts STXBP1 Gene Therapy Trial After First Pediatric Participant Dies

Kriya Nets $320 Million Series D as Odyssey Raises $213 Million and Amgen Retools Research Leadership

Single Birth Injection Protects Primates From HIV, Paves Way for Newborn Safety Trials

Precision RNA Therapy Reverses Progeria in Preclinical Models

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion

mRNA Nanoparticles Reverse HIV Latency in Resting T Cells